摘要
目的探讨围绝经期妇女应用左归丸预防骨质疏松症的有效性和安全性。方法选取2018年6月—2018年12月期间成都中医药大学附属医院接诊的66例围绝经期卵巢功能减退妇女作为研究对象,按随机数字表法分为治疗组和对照组,每组各33例。对照组为空白对照观察,治疗组应用左归丸治疗3个月。观察比较两组围绝经期卵巢功能减退妇女绝经后骨质疏松症发生率,治疗前、绝经后雌激素[卵泡刺激素(Follicle stimulating hormone,FSH)、卵泡刺激素/促黄体生成素(Follicle stimulating hormone/luteinizing hormone,FSH/LH)、雌二醇(Estradiol,E_(2))]、骨密度(Bone mineral density,BMD)Th17/Treg亚群[维甲酸受体相关核孤儿受体γt(Retinoic acid receptor-related orphan receptorsγt,IRORγt)、叉头状转录因子p3(Transcription factor forkhead box p3,Foxp3)]指标及不良反应发生情况。结果治疗后治疗组妇女绝经后骨质疏松症检出率为9.09%(3/33),明显低于对照组的42.42%(14/33),差异有统计学意义(P<0.05)。治疗组绝经后的肾虚证检出率6.06%(2/33)明显低于对照组48.48%(16/33),差异有统计学意义(χ^(2)=14.972,P<0.05)。对照组绝经后FSH、FSH/LH水平均较治疗前明显升高,E_(2)、BMD水平均较治疗前明显降低,差异有统计学意义(P<0.05);治疗组绝经后FSH水平较治疗前升高,E_(2)水平较治疗前降低,差异有统计学意义(P<0.05),FSH/LH、BMD水平无明显变化,差异无统计学意义(P>0.05)。治疗组绝经后FSH、FSH/LH、E_(2)及BMD水平均优于对照组,两组比较差异有统计学意义(P<0.05)。对照组绝经后IRORγt水平较治疗前明显升高,Foxp3水平较治疗前明显降低,差异有统计学意义(P<0.05);治疗组绝经后IRORγt、Foxp3水平较治疗前变化不明显,差异无统计学意义(P>0.05)。治疗组绝经后的IRORγt水平明显低于对照组,Foxp3水平明显高于对照组,差异有统计学意义(P<0.05)。治疗组治疗期间无明显不良反应发生
Objective To explore the efficacy and safety of Zuogui Pills in preventing osteoporosis in perimenopausal women.Methods A total of 66 perimenopausal women with ovarian dysfunction treated in the Hospital of Chengdu University of Traditional Chinese Medicine from June 2018 to December 2018 were selected and divided into treatment group and control group(33 in each group)according to the random number table.The control group was set for blank control observation.The treatment group was treated with Zuogui Pills for 3 months.The incidence of postmenopausal osteoporosis and the changes of estrogen[follicle stimulating hormone(FSH),follicle stimulating hormone/luteinizing hormone(FSH/LH),estradiol(E_(2))],bone mineral density(BMD)and Th17/Treg subsets[retinoic acid receptor-related orphan receptorsγt(IRORγt),transcription factor forkhead box p3(Foxp3)]before and after treatment were compared between the two groups.Results The detection rate of postmenopausal osteoporosis in the treatment group was 9.09%(3/33),which was lower than 42.42%(14/33)in the control group(P<0.05).The detection rate of kidney deficiency syndrome in the treatment group was also lower than that in the control group[6.06%(2/33)vs 48.48%(16/33),χ^(2)=14.972,P<0.05].Compared with the conditions before treatment,the levels of FSH,FSH/LH,and IRORγt in the control group increased,while the levels of E_(2),BMD and Foxp3 decreased(P<0.05);the level of FSH increased while that ofE_(2) decreased in the treatment group(P<0.05),and the levels of FSH/LH,BMD,IRORγt and Foxp3 did not change significantly(P>0.05).Compared with the conditions in the control group,the levels of FSH,FSH/LH and IRORγt in the treatment group were lower,and the levels of E_(2),BMD and Foxp3 were higher(P<0.05).Conclusion Zuogui Pills could inhibit the decrease of estrogen level,improve BMD and effectively prevent the occurrence of osteoporosis in perimenopausal women,without obvious adverse reactions.Therefore,the prescription was safe and effective to prevent osteoporosis.
作者
刘艺
邓琳雯
孙国娟
LIU Yi;DENG Lin-wen;SUN Guo-juan(Maternity Rehabilitation Center,Hospital of Chengdu University of Traditional Chinese Medicine,Chengdu Sichuan 610032;Department of Gynecology,Hospital of Chengdu University of Traditional Chinese Medicine,Chengdu Sichuan 610032;International Department of Gynecology,Hospital of Chengdu University of Traditional Chinese Medicine,Chengdu Sichuan 610032)
出处
《世界中西医结合杂志》
2022年第9期1775-1779,共5页
World Journal of Integrated Traditional and Western Medicine
关键词
左归丸
骨质疏松症
卵巢功能减退
雌激素
骨密度
Zuogui Pills
Osteoporosis
Ovarian dysfunction
Estrogen
Bone mineral density
